Sino Biopharmaceutical’s Stock Price Drops to 2.82 HKD, Experiencing a 3.42% Decline

Sino Biopharmaceutical (1177)

2.82 HKD -0.10 (-3.42%) Volume: 58.86M

Sino Biopharmaceutical’s stock price plunges to 2.82 HKD, marking a -3.42% dip this trading session with a trading volume of 58.86M, reflecting a year-to-date percentage change of -18.73%, underlining the volatile market conditions for investors.

Latest developments on Sino Biopharmaceutical

As analysts revise their estimates of Sino Biopharmaceutical Limited (HKG:1177), the company’s stock price has seen notable movements today. UOB Kay Hian has raised the target price (TP) of Sino Biopharmaceutical to $3.8, anticipating revenue growth to accelerate in 2024. However, Goldman Sachs has lowered the TP to $4.02, citing an expected weak second half of 2023. These revisions reflect the changing outlook on the future of Sino Biopharmaceutical.

A look at Sino Biopharmaceutical Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Sino Biopharmaceutical Limited has been given an overall outlook score of 3 out of 5 by Smartkarma based on their Smart Scores. This indicates that the company has a moderate outlook for the long-term. Sino Biopharmaceutical has received a score of 3 for both value and resilience, showing that the company is performing adequately in these areas. However, it has received a lower score of 2 for growth, suggesting that there may be some challenges in this aspect of the company’s performance. Additionally, Sino Biopharmaceutical has received a score of 3 for both dividend and momentum, indicating that they are performing relatively well in these areas.

Based on a summary of the company’s description, Sino Biopharmaceutical Limited focuses on the research, development, production, and sale of biopharmaceutical products for ophthalmia and Chinese medicine for the treatment of hepatitis. With an overall outlook score of 3 out of 5 from Smartkarma, it can be inferred that the company has a moderate long-term outlook. While they are performing well in terms of value, resilience, dividend, and momentum, there may be some challenges in terms of growth. Investors should consider this information when making decisions about investing in Sino Biopharmaceutical Limited.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma